Navigation Links
ETEX Announces Supply Agreement with AlloSource
Date:4/24/2008

CAMBRIDGE, Mass., April 24 /PRNewswire/ ETEX Corporation, an advanced biomaterials company, announced today that it has entered into a supply agreement with AlloSource.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO )

AlloSource will provide ETEX with Demineralized Bone Matrix (DBM) powder to be mixed with ETEX's proprietary, nanocrystalline, fast setting calcium phosphate to form EquivaBone(TM).

This agreement is consistent with ETEX's multi-source tissue acquisition strategy, allowing ETEX to address the market demand for an osteoinductive DBM product that is designed to flow and set hard once implanted. ETEX will manufacture EquivaBone(TM) in its Cambridge facilities and market the product through its newly formed direct distribution channel.

Brian Ennis, CEO of ETEX Corporation, states "ETEX is pleased to form a partnership with AlloSource and we look forward to a long relationship. We are impressed with the capabilities, service levels, and commitment to excellence that AlloSource provides."

About ETEX Corporation

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit http://www.etexcorp.com.

About AlloSource

Founded in 1994, AlloSource, of Centennial, Colorado is one of the nation's largest non-profit providers of bone and soft tissue allografts for use in a host of medical treatments. Honoring the gift of donation, AlloSource responsibly develops, processes and distributes life-saving and life-enhancing human tissue for our communities. For more information, go to http://www.allosource.org.


'/>"/>
SOURCE ETEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Feb. 20, 2017  Former NFL players who had repeated ... later in life, according to a preliminary study released today ... 69th Annual Meeting in Boston , April ... complex movements where the muscles and nerves work together, like ... ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... Corporation ventured outside of weighing equipment with the goal of expanding the reach ... mind, the line of Starter water analysis meters were introduced into the market ...
(Date:2/18/2017)... ... February 17, 2017 , ... A ... in Hong Kong. , Nerium International is proud to introduce its Age-Defying Night ... Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain ...
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a global ... development of a novel system for quantitative immunohistochemistry ... the University of Rochester (NY, USA) and Konica-Minolta ... new system is able to accurately quantify the ... (Human epidermal growth factor receptor-2) in clinical samples. ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
Breaking Biology News(10 mins):